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immunoprecipitation using antibodies for histone H3 and 
H4 trimethylated at lysines 9 (H3K9), 27 (H3K27), 79 
(H3K79), and 20 (H4K20) revealed that these trimethyl-
ated residues bind strongly to C9orf72 expanded repeats in 
brain tissue, but not to non-pathogenic repeats. Our finding 
that C9orf72 mrNA levels are reduced in the frontal corti-
ces and cerebella of c9FTD/AlS patients is consistent with 
trimethylation of these histone residues, an event known 
to repress gene expression. Moreover, treating repeat 
carrier-derived fibroblasts with 5-aza-2-deoxycytidine, a 
DNA and histone demethylating agent, not only decreased 
C9orf72 binding to trimethylated histone residues, but also 
increased C9orf72 mrNA expression. Our results provide 
compelling evidence that trimethylation of lysine residues 
within histones H3 and H4 is a novel mechanism involved 
in reducing C9orf72 mrNA expression in expanded repeat 
carriers. Of importance, we show that mutant C9orf72 
binding to trimethylated H3K9 and H3K27 is detectable 
in blood of c9FTD/AlS patients. Confirming these excit-
ing results using blood from a larger cohort of patients may 
establish this novel epigenetic event as a biomarker for 
c9FTD/AlS.
Keywords Amyotrophic lateral sclerosis · 
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Introduction
Amyotrophic lateral sclerosis (AlS) and frontotemporal 
dementia (FTD) are two devastating neurodegenerative dis-
eases seen in comorbidity in up to 50 % of patients affected 
with either disease [23, 28]. AlS, the most frequently 
occurring motor neuron disease [26], is characterized by 
Abstract Individuals carrying (ggggCC) expanded 
repeats in the C9orf72 gene represent a significant por-
tion of patients suffering from amyotrophic lateral sclero-
sis (AlS) and frontotemporal dementia (FTD). elucidat-
ing how these expanded repeats cause “c9FTD/AlS” has 
since become an important goal of the field. Toward this 
end, we sought to investigate whether epigenetic changes 
are responsible for the decrease in C9orf72 expression lev-
els observed in c9FTD/AlS patients. We obtained brain 
tissue from ten c9FTD/AlS individuals, nine FTD/AlS 
cases without a C9orf72 repeat expansion, and nine dis-
ease control participants, and generated fibroblastoid cell 
lines from seven C9orf72 expanded repeat carriers and 
seven participants carrying normal alleles. Chromatin 
V. V. Belzil and P. O. Bauer contributed equally to this work.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-013-1199-1) contains supplementary 
material, which is available to authorized users.
V. V. Belzil · P. O. Bauer · M. Prudencio · T. F. gendron · 
C. T. Stetler · l. Pregent · l. Daughrity · M. C. Baker · 
r. rademakers · D. W. Dickson · l. Petrucelli (*) 
Department of research, Neuroscience, Mayo Clinic College 
of Medicine, 4500 San Pablo road, Jacksonville, Fl 32224, USA
e-mail: petrucelli.leonard@mayo.edu
I. K. Yan 
Department of Cancer Biology, Mayo Clinic College 
of Medicine, 4500 San Pablo road, Jacksonville, Fl 32224, USA
K. Boylan 
Department of Neurology, Mayo Clinic, 4500 San Pablo road, 
Jacksonville, Fl 32224, USA
T. C. Patel 
Department of Transplantation, Mayo Clinic, 4500 San Pablo 
road, Jacksonville, Fl 32224, USA
896 Acta Neuropathol (2013) 126:895–905
1 3
degeneration of upper and lower motor neurons leading 
to muscle weakness, spasticity and atrophy during mid-
adulthood, with patients having a mean life expectancy of 
3–5 years after disease onset [7]. Frontotemporal dementia 
is one of the most frequent presenile onset dementias [19], 
with neuronal degeneration in the frontal and temporal 
lobes causing a progressive deterioration of behavior, per-
sonality and/or language [24]. recent findings demonstrate 
that an expanded non-coding hexanucleotide (ggggCC) 
repeat in the chromosome 9 open reading frame 72 
gene (C9orf72, OMIM *614260) is the most common 
known cause of FTD and AlS, collectively referred to as 
c9FTD/AlS [16, 36]. Mutation carriers have several hun-
dred to several thousand copies of the (ggggCC) hexa-
nucleotide repeat, as compared to 30 or less copies in non-
pathogenic carriers [16]. This discovery provided further 
evidence that the two diseases result from defects in the 
same or overlapping biological pathways.
recent studies have suggested that C9orf72 repeat 
expansions may lead to rNA-mediated toxicity through the 
formation of rNA foci that possibly sequester rNA-bind-
ing proteins, as well as repeat associated non-ATg (rAN) 
translation leading to the synthesis of aggregation-prone 
c9rAN proteins [2, 16, 30]. Decreases in C9orf72 mrNA 
levels in brain and lymphoblasts of repeat expansion car-
riers have also been reported [16, 22, 36], indicating that 
loss of C9orf72 function may also play a role in disease 
pathogenesis. Moreover, the finding that downregulation of 
the zebrafish orthologue of C9orf72 leads to both altered 
morphology of motor neuron axons and locomotor deficits, 
and that these features are reversed upon overexpression of 
wild-type human C9orf72, further support the notion that 
C9orf72 loss of function is detrimental [14]. Dual involve-
ment of rNA toxicity and loss of function have been impli-
cated in a variety of neurodegenerative diseases caused by 
repeat expansions, including myotonic dystrophy, spinocer-
ebellar ataxia (SCA) types 8 and 31, and Fragile X-associ-
ated tremor/ataxia syndromes [35].
Increasing evidence suggests that repeat expansions 
can impair mrNA expression through epigenetic changes 
resulting from variation in DNA and histone methyla-
tion, which lead to aberrant binding of the transcrip-
tional machinery as a consequence of heterochromatin 
formation [1, 4, 15, 27, 32, 41]. epigenetic changes and 
altered mrNA expression have previously been linked to 
FTD/AlS pathogenesis. For instance, aberrant epigenetic 
regulation of granulin (GRN), the gene that encodes pro-
granulin (PgrN) and is mutated in about 5–10 % of the 
total FTD population, causes a decrease in GRN mrNA 
expression [18]. Of interest, protein levels of DNA meth-
yltransferases (DNMTs), which induce DNA meth-
ylation by catalyzing methyl group transfer to cytosine 
residues in regulatory regions, increase pre-apoptotically 
in mouse motor neurons [13], and DNMT1, DNMT3a, 
and 5-methylcytosine are all upregulated in motor neu-
rons of AlS patients [13]. DNMT1 has been reported to 
function as a maintenance methyltransferase both in repeat 
regions and repetitive genomic sequences characterized by 
a higher frequency of cytosine–guanine sequences, known 
as cytosine–phosphate–guanine (Cpg) islands, whereas 
DNMT3 mainly functions in Cpg islands. These islands, 
which are normally not methylated in active genes, 
are usually methylated to suppress gene expression of 
imprinted genes [9]. An observed-to-expected Cpg ratio 
greater than 60 % predicts Cpg islands in a genomic DNA 
region larger than 200 bp [20]. Based on this criterion, the 
observed-to-expected Cpg ratio is 75 % in patients carry-
ing 700–1,600 (ggggCC) copies. This suggests the pres-
ence of a newly formed Cpg island spanning the repeat 
region that is potentially at risk of abnormal methylation 
in expansion carriers. given that methylation of repeat 
sequences, as well as hypermethylation of adjacent Cpg 
islands within promoter regions, has been shown to aber-
rantly influence histone methylation processes leading to 
gene silencing and consequently loss of protein function 
[1, 37], we sought to determine whether a similar disease 
cascade occurs in c9FTD/AlS.
To elucidate the mechanisms causing decreased expres-
sion of C9orf72 mrNA in mutation carriers [16, 22, 36], 
which could lead to loss of C9orf72 function, we investi-
gated whether perturbed epigenetic processes are involved. 
Our results clearly demonstrate that trimethylation of his-
tones H3 and H4 at several lysine residues is a novel mech-
anism involved in decreasing the expression of C9orf72 
mrNA in expanded repeat carriers. In addition, using 
peripheral blood of two expanded repeat carriers, we con-
firmed that these epigenetic changes are easily detectable. 
Future studies will need to confirm blood detection of epi-
genetic changes in a larger cohort of c9FTD/AlS patients 
to validate the biomarker capacity of this novel epigenetic 
event.
Materials and methods
Standard protocol approvals, registrations, and patient 
consents
Protocols were approved by the Mayo Clinic Institutional 
review Board and ethics Committee on human experimen-
tation. All participants or authorized family members gave 
written informed consent after which participant and fam-
ily information was gathered, skin biopsies were collected, 
or post-mortem analyses were performed.
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Subjects
All participants in this study were recruited at Mayo Clinic 
Florida and were independently ascertained as having AlS 
and/or FTD by trained neurologists. Frontal cortices and 
cerebella tissues were obtained after post-mortem analyses 
from four AlS and six FTD patients carrying the C9orf72 
expansion, four AlS and five FTD cases without C9orf72 
expansion, and nine disease control participants (clini-
cal information in online resource, Table 2). Skin biopsies 
were collected from a total of seven C9orf72 expansion car-
riers, including two healthy carriers of 28 and 30 years of 
age, and seven participants carrying normal alleles (clini-
cal information in online resource, Table 3). Blood samples 
were obtained from two AlS patients carrying the repeat 
expansion, and two AlS cases carrying normal alleles 
(clinical information in online resource, Table 4).
Maintenance and treatment of fibroblasts
Fibroblasts were derived from skin sampled by punch 
biopsy on the anterior aspect of the forearm. Fibroblasts 
were maintained in Dulbecco’s modified eagle’s medium 
(lonza, Basel, Switzerland) supplemented with 10 % heat-
inactivated fetal bovine serum (Sigma-Aldrich, St-louis, 
MO, USA), 100 units/ml penicillin, and 100 μg/ml strepto-
mycin (gibco, Carlsbad, CA, USA) at 37 °C, in an atmos-
phere containing 5 % CO2 and 95 % air. Cells were treated 
with 2 μM 5-aza-2-deoxycytidine (5-AZA) or dimethyl 
sulfoxide (DMSO) for 6 days before they were harvested 
for further experiments.
Quantitative real-time polymerase chain reaction 
(qrT-PCr)
Total rNA was extracted from fibroblasts using Trizol 
(Invitrogen, Carlsbad, CA, USA) and from brain tis-
sue using the rNAeasy Plus Micro Kit (QIAgeN, Venlo, 
limberg, Netherlands) as per manufacturer’s instructions. 
rNA integrity was verified on an Agilent 2100 bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). cDNA was 
obtained after reverse transcription polymerase chain reac-
tions (rT-PCr) using approximately 1 μg of rNA with 
random primers and the High Capacity cDNA Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA) as per 
manufacturer’s instructions. Following standard protocols, 
qrT-PCr was conducted in triplicates for all samples using 
inventoried TaqMan gene expression assays for C9orf72 
transcript variants 1 (NM_145005.5), 2 (NM_018325.3) 
and  3 (NM_001256054.1) (Hs00376619), C9orf72 tran-
script variants 2 and  3 (Hs00945132), C9orf72 transcript 
variant 1 (Hs00331877), GAPDH (Hs00266705), and H19 
(Hs 00262142) (Applied Biosystems) on an ABI Prism 
7900HT Fast real-Time PCr System (Applied Biosys-
tems). relative quantification was determined using the 
ΔΔCt method and normalized to GAPDH.
Droplet digital PCr (ddPCr)
rNA was isolated from brain tissue using the rNAe-
asy Plus Micro Kit (QIAgeN) and cDNA was obtained 
by reverse transcription using random primers and the 
High Capacity cDNA Transcription Kit (Applied Biosys-
tems) as per manufacturer’s instructions. reaction mix-
tures were prepared for droplet digital PCr using 4 μl of 
reverse transcribed product, 10 μl of ddPCr 2x Master 
Mix (Bio-rad, Hercules, CA, USA), 1 μl of 20x Primer 
and TaqMan Probe assays for C9orf72 transcript variant 1, 
2 and  3 (Hs00376619), C9orf72 transcript variant 2 and  3 
(Hs00945132), C9orf72 transcript variant 1 (Hs00331877) 
(Applied Biosystems), and 5 μl of nuclease-free water, 
per reaction mixture. The negative control contained water 
only. emulsified 1 nl reaction droplets were generated 
using a QX100 Droplet generator (Bio-rad) and a drop-
let generator Dg8 cartridge (Bio-rad) containing 20 μl of 
reaction mixture and 70 μl of ddPCr droplet generation 
oil (Bio-rad) per well. Thirty-five microliters of the gen-
erated droplet emulsions were transferred to 96-well PCr 
plates which were heat-sealed using foil sheets. Target 
DNA amplification was performed by thermal cycling the 
droplet emulsions as follows: initial denaturation at 95 °C 
for 10 min, followed by 40 cycles of 94 °C for 30 s and 
60 °C for 1 min, then 98 °C for 10 min. The fluorescence 
of each thermal cycled droplet was measured using the 
QX100 droplet reader (Bio-rad). Data was analyzed using 
the QuantaSoft software (Bio-rad) after threshold setting 
on fluorescence of negative controls.
Chromatin immunoprecipitation (ChIP)
Fibroblasts grown in 10 cm culture plates at 90–95 % con-
fluency were treated with DMSO or 5-AZA followed by 
incubation with 1 % formaldehyde at 37 °C for 10 min 
for crosslinking. glycine (125 mM) was then added and 
cells were incubated at room temperature for 5 min to 
quench the crosslinking. Fibroblasts were washed with ice 
cold PBS, scraped and pelleted by brief centrifugation at 
13,000×g. Cell pellets were resuspended in 500 μl SDS 
lysis buffer (eMD Millipore, Billerica, MA, USA) con-
taining protease inhibitors and incubated on ice for 10 min. 
DNA was sheared by four 10 s-on/30 s-off cycles of son-
ication at 35 % output. 100 μl of each sample was then 
diluted with 900 μl ChIP dilution buffer (eMD Millipore). 
For pre-cleaning, the samples were incubated with 40 μl 
of Protein A Agarose slurry (eMD Millipore) with rotation 
for 1 h at 4 °C. Samples were then incubated overnight at 
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4 °C with 2 μg of anti-(pan)H3 (eMD Millipore) or anti-
H3K9me3 (Diagenode, Denville, NJ, USA). ChIP from 
brain samples was performed using 50–70 mg of tissue 
homogenized using a tissue grinder after crosslinking 
and quenching, and following the same procedure used 
for fibroblasts with the exception that samples were incu-
bated overnight at 4 °C with 2 μg of anti-(pan)H3 and H4 
(eMD Millipore), as well as anti-H3K9me3, H3K27me3, 
H3K79me3, H4K20me3 (Diagenode). Overnight incu-
bation with antibodies was followed by a 3 h incubation 
with 50 μl agarose slurry at 4 °C. ChIP from blood was 
performed using mononuclear cells isolated using stand-
ard conditions, and washed twice using HANK’S solu-
tion (life Technologies, Carlsbad, CA, USA). DNA was 
sheared by six 10 s-on/30 s-off cycles of sonication at 
30 % output, then subjected to the same ChIP procedure 
as used for fibroblast studies. However, overnight incuba-
tion at 4 °C was performed using 1 μg of anti-(pan)H3 
(eMD Millipore), anti-H3K9me3, and anti-H3K27me3 
(Diagenode) antibodies followed by a 3 h incubation with 
25 μl agarose slurry at 4 °C. The bound complexes for the 
three experiments were washed for 10 min at room tem-
perature with rotation, first with low salt immune com-
plex wash buffer, followed by high salt and liCl immune 
complex wash buffers (all from eMD Millipore), and two 
final washes with Te buffer. After the final wash with 
Te buffer, the agarose was incubated with freshly pre-
pared ChIP elution buffer (0.1 M NaHCO3, 1 % SDS) for 
20 min at room temperature with rotation, after which the 
agarose beads were discarded. After reverse crosslinking 
with 200 mM NaCl at 65 °C either overnight for the fibro-
blast and brain studies, or 6 h for the blood study, samples 
were treated with 0.5 μg/μl Proteinase K for 90 min at 
45 °C. The eluted DNA was purified using a DNA Clean-
up kit (Zymo research, Irvine, CA, USA) for the analy-
sis. For semi-quantitative (semi-q) PCr, forward primer 
5′AgAgggTgggAAAAACAAAAACAC3′ and reverse 
primer 5′AAAACCACgAAATCgTCTTCACTT3′ were 
designed using PrimerSelect (DNASTAr, Madison, WI, 
USA). DNA amplification was conducted by PCr using 
1 μl of ChIP-obtained DNA, 0.75 μl dNTP, 1.5 μl 10x 
standard buffer (including 1.5 mM final MgCl2 concen-
tration), 0.6 μl of each primer, 10.25 μl of nuclease-free 
water, and 0.3 μl of Apex Taq Polymerase (genesee Scien-
tific) per reaction mixture, and was run on a Mastercycler 
proS (eppendorf). For each fragment, a denaturation step 
of 5 min was first performed at 95 °C. After that, a touch-
down protocol was used which consisted of an initial cycle 
of 20 s denaturation at 94 °C, 20 s annealing at 65 °C and 
30 s elongation at 72 °C. This was followed by ten cycles 
in which the annealing temperature was decreased each 
time by 1 °C. Then 40 cycles of 20 s denaturation at 94 °C, 
20 s annealing at 58 °C and 30 s elongation at 72 °C were 
run. A final extension at 72 °C was performed for 5 min. 
DNA products were electrophoresed in a 2 % agarose gel.
Statistical analysis
We used unpaired Student’s t test for comparison between 
two sample groups with a 95 % confidence level. One-way 
ANOVA followed by Tukey post hoc test was used for mul-
tiple comparisons with a 95 % confidence level. We consid-
ered the difference between comparisons to be significant 
when p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.005).
Results
given that brain tissue analysis of C9orf72 mrNA expres-
sion levels has been limited to the frontal cortex [16, 22], 
we first sought to explore whether C9orf72 mrNA  expres-
sion is similarly decreased in the frontal cortex of our 
cohort of patients, and to evaluate whether a reduction 
is also observed in the cerebellum, another brain region 
affected in c9FTD/AlS [34]. We obtained brain tissue 
samples from ten AlS and FTD C9orf72 repeat carri-
ers (C9orf72+), nine AlS and FTD patients carrying a 
non-pathogenic C9orf72 repeat (C9orf72−), and nine 
C9orf72− disease controls (clinical information in online 
resource, Table 2). We then isolated rNA from cerebella 
and frontal cortices and performed expression assays by 
quantitative real-time polymerase chain reaction (qrT-
PCr) using Taqman probes targeting transcript variants 1, 
2 and 3, as well as transcript variants 2 and 3 (Fig. 1a). As 
transcript variant 1 was difficult to detect through standard 
qrT-PCr, we assessed its expression using a highly precise 
and absolute nucleic acid quantification technique, termed 
droplet digital PCr (ddPCr) [25]. Moreover, we further 
compared expression levels obtained from standard qrT-
PCr with ddPCr (online resource, Fig. 1, Table 1). We 
found that the C9orf72+ group exhibited decreased mrNA 
expression across all assays, as compared to normal repeat 
length carriers and disease control participants (Fig. 1b–e).
We next explored whether this decrease in C9orf72 
expression results from aberrant histone methylation, 
given that trimethylation of histone H3 at lysines 9, 27, 
79, as well as of histone H4 at lysine 20, is linked to gene 
repression [3]. Using brain tissue from all 28 participants, 
we performed chromatin immunoprecipitation (ChIP) 
experiments using anti-H3K9me3, anti-H3K27me3, anti-
H3K79me3, anti-(pan)H3 (total histone H3), as well as 
anti-H4K20me3 and anti-(pan)H4 (total histone H4). We 
successfully amplified the C9orf72 promoter region in 
pathogenic repeat carriers, and found that the trimethyl-
ated residues only bind strongly to C9orf72 repeat expan-
sions (Fig. 2a–e). Of note, the C9orf72 genomic region 
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was amplified in all samples precipitated by both anti-(pan)
H3 and anti-(pan)H4 (complete results in online resource, 
Fig. 2), confirming normal C9orf72 binding to histones H3 
and H4.
To confirm that reduced mrNA expression results 
from aberrant binding of expanded repeats to trimethyl-
ated lysine residues in c9FTD/AlS, we treated fibroblasts 
obtained from seven participants carrying normal alleles 
(C9orf72−) and seven patients carrying a (ggggCC) 
repeat expansion (C9orf72+) (clinical information in 
online resource, Table 3) with 5-aza-2-deoxycytidine 
(5-AZA), a well-known DNA and histone demethylat-
ing agent [31, 33]. Following rNA isolation and reverse 
transcription, we conducted expression assays by qrT-
PCr using probes targeting C9orf72 transcript variants 1, 
2 and 3, as well as transcript variants 2 and 3. Follow-
ing 5-AZA treatment, C9orf72 mrNA expression was 
significantly increased in fibroblasts from (ggggCC) 
Fig. 1  Frontal cortex and cerebellum tissue samples from the 
C9orf72+ group exhibit a significant decrease in C9orf72 mrNA 
expression levels. a Schematic representation showing the three 
known transcript variants of C9orf72. The star marks the repeat 
location. b, c qrT-PCr for C9orf72 transcript variants 1, 2, 3 and 
C9orf72 transcript variants 2, 3 were performed in frontal cortex 
(b) and cerebellum (c). Data on graphs were normalized to disease 
control group (mean value set to 1). Statistical differences were cal-
culated by one-way ANOVA with Tukey post hoc test. *p < 0.05, 
**p < 0.01, ***p < 0.005. d, e ddPCr was used to calculate abso-
lute levels of the less abundant C9orf72 transcript variant 1 in frontal 
cortex (d) and cerebellum (e). Transcript expression is expressed as 
number of copies per microliter. The mean expression and the range 
of expression across all samples tested are shown for each group. 
A clinical description of participants is available in Table 2 (online 
resource)
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repeat expansion carriers, an effect not observed in fibro-
blasts from participants carrying normal alleles (Fig. 3a, 
b). However, mrNA expression of H19, an imprinted 
gene, was increased in both pathological and normal 
repeat carriers following 5-AZA treatment (Fig. 3c). Con-
sistent with our brain ChIP experiments, we found that 
H3K9me3 strongly binds to C9orf72 repeat expansions in 
DMSO-treated C9orf72+ fibroblasts but not in C9orf72− 
fibroblasts. Of importance, the 5-AZA-induced increase 
in C9orf72 mrNA expression in C9orf72+ fibroblasts 
was accompanied by a decrease in binding of the C9orf72 
promoter to H3K9me3 (Fig. 3d, e). Similar to our studies 
using brain tissue, we found normal binding of C9orf72 
to histone H3 in all fibroblasts after precipitating samples 
with anti-(pan)H3 (Fig. 3f) (complete results in online 
resource, Fig. 3).
Finally, to determine whether these biological changes 
are detectable in peripheral blood, we isolated mononu-
clear cells from blood collected from two repeat expansion 
carriers (C9orf72+) and two participants carrying normal 
alleles (C9orf72−), and conducted ChIP experiments using 
anti-H3K9me3, anti-H3K27me3, and anti-(pan)H3. As in 
the brain, we confirmed that only mutant C9orf72 strongly 
binds H3K9me3 and H3K27me3, despite normal binding 
of the C9orf72 promoter region to histone H3 in all four 
samples (Fig. 4).
Our experiments provide compelling evidence that 
repression of the C9orf72 gene in pathogenic (ggggCC) 
Fig. 2  reduced C9orf72 mrNA expression levels in the C9orf72+ 
group result from aberrant binding to trimethylated histone residues. 
a electrophoretic representation of chromatin immunoprecipitated 
DNA in a subgroup of participants tested. Chromatin immunopre-
cipitation (ChIP) was performed on two different human tissues, 
frontal cortex (F) and cerebellum (C), using antibodies specific for 
total histones H3 and H4 or trimethylated histones H3K9, H3K27, 
H3K79, and H4K20. Following pull-down, bound DNA was puri-
fied and used for PCr amplification of the C9orf72 promoter region. 
This region was successfully amplified in the C9orf72+ group when 
ChIP was carried out with antibodies targeting trimethylated histone 
residues; under the same conditions, this region was not amplified in 
C9orf72− and disease controls, indicating an absence of binding. The 
complete figure is provided in the online resource. b, c, d, e rela-
tive quantifications of all brain DNA were performed by measuring 
band intensity (complete gels in the online resource, Fig. 2) for each 
immunoprecipitated histone and presented as a ratio to the input. 
each graph is normalized to total histone levels in the disease control 
group (mean value set to 1). Statistical differences were calculated by 
one-way ANOVA with Tukey post hoc test.  *p < 0.05, **p < 0.01, 
*** p < 0.005.  A clinical description of participants is available in 
Table 2 (online resource)
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repeat carriers is caused by the binding of mutant C9orf72 
to trimethylated lysine residues within histones H3 and H4.
Discussion
In this study, we show that the decrease in C9orf72 expres-
sion levels in brain tissue and fibroblasts derived from 
pathogenic C9orf72 expansion carriers is associated with 
enhanced binding of mutant C9orf72 to trimethylated 
lysine residues within histones H3 and H4. We also dem-
onstrate that these epigenetic changes are detectable in 
peripheral blood, a finding that, when confirmed in a larger 
cohort of patients, may represent a disease-specific bio-
marker of c9FTD/AlS.
Our data suggest that the decrease in C9orf72 mrNA 
expression results from heterochromatin formation follow-
ing aberrant histone methylation. As C9orf72 expansions 
are mostly inherited in an autosomal dominant fashion, 
heterozygous C9orf72 expanded repeat carriers carry both 
a wild-type transcriptionally active allele (euchromatin), as 
well as a mutated transcriptionally silent allele (heterochro-
matin). The wild-type allele is most likely unable to pro-
duce enough C9orf72 protein to compensate for the loss of 
Fig. 3  C9orf72 mrNA expression is increased and H3K9me3 bind-
ing is decreased in C9orf72+ fibroblasts upon 5-AZA treatment. a, b 
qrT-PCr of rNA obtained from human fibroblasts grown in DMSO 
or 5-AZA demethylating agent. Both assays targeting transcript vari-
ants 1, 2, 3 (a) and 2, 3 (b) show a significant increase in expression 
after 5-AZA treatment only in C9orf72 repeat expansion carriers. c 
qrT-PCr of H19, an imprinted gene, showing effectiveness of the 
5-AZA treatment in C9orf72+ and C9orf72− fibroblasts. Statisti-
cal differences were assessed by unpaired Student t test. *p < 0.05, 
**p < 0.01. NS no significant difference. d electrophoretic repre-
sentation of chromatin immunoprecipitated DNA from a fibroblast 
subgroup using antibodies specific for total H3 or trimethylated his-
tone H3K9. Fibroblasts were grown in DMSO or 5-AZA. Chroma-
tin immunoprecipitation (ChIP) was performed in fibroblasts from 
C9orf72+ and C9orf72− participants. Following pull-down, bound 
DNA was purified and used for PCr amplification of the C9orf72 
promoter region. Upon treatment with vehicle (DMSO), the bind-
ing to trimethylated histone H3K9  in C9orf72+ cells, as assessed 
by the level of amplified C9orf72 promoter region, was higher as 
compared to C9orf72−. Treatment with 5-AZA reduced this bind-
ing in C9orf72+ cases. The complete figure of all fibroblast lines is 
provided in the online resource. e, f relative quantifications of all 
fibroblast lines were performed by measuring band intensity (com-
plete gels in the online resource, Fig. 3) for each immunoprecipitated 
histone and presented as a ratio to the input. graphs are normalized 
to total histone levels of disease control group (mean value set to 
1). Statistical differences were calculated by one-way ANOVA with 
Tukey post hoc test. *p < 0.05. A clinical description of participants 
is available in Table 3 (online resource)
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protein from the mutated allele, thereby leading to haplo-
insufficiency (Fig. 5). As histone methylation is commonly 
perceived as inducing flexible short-term gene silencing 
through regulation of numerous histone-modifying com-
plexes, regulation of the chromatin structure varies depend-
ing on the availability of chromatin remodeling enzymes, 
including histone acetyltransferases, histone deacetylases, 
histone methyltransferases and histone demethylases. This 
dynamic chromatin structure likely influences transcrip-
tion of expanded C9orf72, which consequently might either 
accumulate as rNA foci or translate into aggregation-prone 
c9rAN proteins.
While our studies were in progress, the rogaeva’s group 
reported DNA hypermethylation of the upstream Cpg 
island in about 40 % of all AlS cases that were tested [43]. 
Although they found no hypermethylation in about 60 % 
of the AlS cases studied, it remains possible that another 
Cpg island located farther away from the repeat might be 
methylated in these patients. Several Cpg sites within the 
repeat itself may also be methylated, as suggested by the 
methyl-sensitive restriction enzyme digest and sequenc-
ing (Mre-seq) Cpg score tool (http://genome.ucsc.edu). 
Of note, the number of Cpg sites in the repeat region is 
increased in expansion carriers, creating a new Cpg island 
that can be a target for methylation. Future studies will 
need to determine whether the expanded repeat as well as 
nearby Cpg islands are methylated, and estimate the fre-
quency of aberrant DNA methylation in both AlS and FTD 
cases. While DNA methylation is commonly believed to 
trigger histone methylation, we now know that methylation 
of either DNA or histone residues can appear first, leading 
to aberrant methylation of the other structure [10]. If DNA 
methylation appears first, it must happen well before the 
onset of symptoms; increased binding of mutant C9orf72 
to trimethylated histone H3K9 was similarly present in 
two asymptomatic repeat carriers (28 and 30 years of age) 
and in patients already diagnosed with AlS or FTD (clini-
cal information in online resource, Table 3). The expanded 
repeat may also lead to an unusual DNA structure, increas-
ing DNMTs’ capacity to catalyze methyl groups to cyto-
sine residues within the repeat itself. This aberrant DNA 
methylation in turn may trigger methylation of histones 
H3 and H4. regardless of which structure becomes meth-
ylated first, our findings support the notion that it is the 
aberrant methylation of histones H3 and H4  residues in 
all c9FTD/AlS patient samples evaluated that caused the 
decreased expression of C9orf72 mrNA.
The expanded non-coding (ggggCC) repeat, which 
is located between two alternatively spliced non-coding 
5′ exons of C9orf72, produces three distinct transcript 
Fig. 4  Strong binding of expanded C9orf72 to H3K9me3 and 
H3K27me3 is detectable in the blood of c9FTD/AlS patients. elec-
trophoretic representation of chromatin immunoprecipitated blood 
DNA from two repeat expansion carriers (C9orf72+) and two par-
ticipants carrying normal alleles (C9orf72−). Antibodies specific 
for total H3 or trimethylated histone H3K9 and H3K27 were used 
to pull-down DNA. Following pull-down, bound DNA was purified 
and used for PCr amplification of the C9orf72 promoter region. The 
binding to trimethylated H3K9 and H3K27 in C9orf72+ blood cells, 
as assessed by the level of amplified C9orf72 promoter region, was 
higher as compared to C9orf72−
Fig. 5  Schematic representation of the proposed haploinsufficiency mechanism resulting from epigenetic changes in c9FTD/AlS
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variants (Fig. 1a). Transcript variants 1 (NM_145005.5) 
and 3 (NM_001256054.1) have the repeat located in the 
intronic region and have been suggested to lead to rNA 
foci formation and rNA-binding protein sequestration, 
while the expression of variant 2 (NM_018325.3), with the 
repeat located in the promoter region, has been shown to 
be silenced in pathogenic repeat carriers [16, 29]. Others 
reported reduced expression of the three known transcript 
variants [22]. given this difference in repeat location and 
considering the involvement of epigenetic changes, the 
transcription level of each variant may not be uniformly 
altered by methylation, thereby resulting in different dis-
ease courses and/or biological outcomes. Such methylation 
variability has previously been shown to strongly influence 
phenotypes in Fragile X and rett syndromes [8, 40]. Future 
studies will need to evaluate whether methylation variabil-
ity similarly influence AlS and FTD phenotypes.
Our results rise important questions regarding the 
mid-adulthood onset of disease, as the methylation pat-
tern of histones H3 and H4 varies with age, increasing or 
decreasing depending on histone residues [11]. Of inter-
est, the trimethylated histone residues aberrantly bound 
by mutant C9orf72 are also known to be methylated in an 
age-dependent manner. Specifically, methylation at resi-
due H3K9 decreases with age, and methylation at residues 
H3K27, H3K79 and H4K20 increases [17, 38, 42]. Moreo-
ver, it is well-known that accumulation of reactive oxygen 
species over time leads to an exponential increase in molec-
ular oxidative stress, an event extensively associated with 
AlS [12], which has been suggested to cause a gradual 
decline in homeostatic mechanisms associated with aging 
[5, 39]. It has also been suggested that epigenetic mecha-
nisms resulting from aging possibly play an important 
physiopathological role in the presence of oxidative stress 
[11]. Oxidative stress is known to alter the balance between 
acetylation/deacetylation and methylation/demethylation 
processes in histone residues, deregulating the expression 
of pro-inflammatory genes. As such, aberrant histone meth-
ylation as a result of C9orf72 repeat expansions, oxidative 
stress accumulation leading to epigenetic deregulation, and 
normal age-related epigenetic mechanism variations could 
all contribute to the adult onset of the disease as well as 
the neuroinflammation found in AlS patients [44]. Since 
c9FTD/AlS histone-associated methylation can be easily 
detected using patient blood, it will be of interest to evalu-
ate whether aberrant histone methylation changes over the 
course of the disease.
Our results suggest that c9FTD/AlS can now be consid-
ered among the class of repeat disorders marked by chroma-
tin modifications, such as myotonic dystrophy, SCA types 
8 and 31, Friedreich ataxia, Fragile X and Fragile X-asso-
ciated tremor/ataxia syndromes [6]. Appropriate chroma-
tin conformation in neurons is essential to prevent DNA 
damage, to assure proper DNA packaging and to maintain 
normal gene expression. Similar to myotonic dystrophy 
and SCA8, three distinct pathogenic processes appear to be 
associated with c9FTD/AlS pathogenesis. First, C9orf72 
repeat expansions lead to the formation of rNA foci, which 
have the potential to sequester rNA-binding proteins and 
impair their function [16, 29]. Second, we and others have 
recently reported that C9orf72 repeat expansions lead to 
rAN translation resulting in the production of poly-gly-
cine–alanine, poly-glycine–arginine and poly-glycine–pro-
line peptides that accumulate as insoluble aggregates in the 
cytoplasm of neurons [2, 30], further supporting an rNA-
mediated mechanism of toxicity in c9FTD/AlS. Third, 
our current study suggests that binding of mutant C9orf72 
to trimethylated lysine residues within histones H3 and H4 
causes repression of the C9orf72 gene, an event that may 
play an important role in the development of c9FTD/AlS. 
Taken together, early studies suggest a C9orf72 loss of 
function, both through neurotoxic processes and epige-
netic changes, as a disease mechanism, and demonstrate 
that a better understanding of the C9orf72 protein func-
tion is crucial in order to identify therapeutic targets and 
to develop effective treatment strategies [21]. Additional 
research to examine DNA and histone methylation as a part 
of c9FTD/AlS pathogenesis may also lead to the identifi-
cation of novel therapeutic targets for AlS and FTD. The 
need for such work is urgent: despite an enormous effort to 
elucidate the molecular mechanisms involved in FTD and 
AlS, the prognosis for patients has not improved, and no 
effective treatment has been developed. The discovery that 
C9orf72 haploinsufficiency contributes to disease pathogen-
esis and that epigenetic processes mediate this effect offers 
a unique opportunity for therapeutic development, provid-
ing c9FTD/AlS patients with new hope.
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